Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer

NCT01041781 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.

NCT NCT01041781
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01041781 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer
Lead sponsor
Alliance for Clinical Trials in Oncology
Phase
Phase 3
Overall status
Terminated
Start date
February 28, 2010
Completion date
March 31, 2018
Enrollment
313 (actual)
Sites
400

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer